SCHEDULE 13G: Soleus Capital Group Discloses 5.2% Stake in Surmodics, Inc.

Soleus Capital Master Fund, L.P. and its affiliated entities, including Guy Levy, have reported a collective beneficial ownership of 5.2% of Surmodics, Inc.'s common stock as of January 21, 2025.

Summary

• Soleus Capital Master Fund, L.P., along with Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, have jointly filed a Schedule 13G.
• The filing reports beneficial ownership of 739,060 shares of common stock in Surmodics, Inc. (CUSIP: 868873100).
• This represents 5.2% of Surmodics, Inc.'s outstanding common stock.
• The percentage is calculated based on 14,326,000 shares outstanding as of November 15, 2024, as reported in Surmodics' Annual Report on Form 10-K filed on November 20, 2024.
• The reporting persons disclaim beneficial ownership of these shares except for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of a significant ownership stake, which is neutral in itself. The presence of a new institutional investor can be viewed positively by some, but the filing itself contains no performance-related information.

Positives

• Disclosure of a significant 5.2% ownership stake by Soleus Capital entities, potentially signaling institutional confidence and interest in Surmodics, Inc.

Risks

• The reporting persons (Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy) disclaim beneficial ownership of the shares held by Soleus Capital Master Fund, L.P. for any purpose other than determining their obligations under Section 13(d) of the Securities Exchange Act of 1934.

Future Outlook

NA

Management Comments

• Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC, and Mr. Levy disclaim beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of them is the beneficial owner of such shares for any other purpose.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor and does not provide broader industry trend analysis. It indicates a specific investment decision within the medical device or healthcare sector where Surmodics, Inc. operates.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor (Soleus Capital Master Fund, L.P.) holding 5.2% of the common stock may influence investor perception and potentially stock trading activity.

Key Dates

Keywords

Surmodics Inc., Soleus Capital Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake, SRDX